SEC Form 4 · accession 0001179110-18-000783
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Helen Torley
Officer — President and CEO · Director
Period of report
Jan 6, 2018
Accepted (ET)
Jan 9, 2018 · 6:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001159036
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 6, 2018 | M | 30,000 | $0.00 | A | 274,159 | D | |
| Common StockF1 | Jan 6, 2018 | F | 11,649 | $19.46 | D | 262,510 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF2 | $0.00 | Jan 6, 2018 | M | 30,000 | D | — | — | Common Stock | 30,000 | 0 | D |
Explanation of responses
- F1The reported disposition of 11,649 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations and was not an open market sale of the shares by the reporting person.
- F2This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.